Cryptococcus neoformans var Cryptococcus neoformans var. neoformans resistant to fluconazole in an HIV-negative patient with chronic lymphocytic leukemia  K. Assing, H. Birgens, M. Arendrup  Clinical Microbiology and Infection  Volume 9, Issue 5, Pages 441-444 (May 2003) DOI: 10.1046/j.1469-0691.2003.00571.x Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 Etest susceptibility testing of fluconazole and amphotericin B. Susceptibility testing was performed according to the manufacturer's recommendations. The isolate was regarded as fluconazole resistant. The Etest endpoint of amphotericin B was 0.25 mg/L. Clinical Microbiology and Infection 2003 9, 441-444DOI: (10.1046/j.1469-0691.2003.00571.x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 2 Seventy-two-hour reading of NCCLS microdilution susceptibility determination. Growth inhibition curve with two-fold drug dilutions and untreated control cultures. OD values read by spectrophotometer. Fluconazole 80% inhibition cut-off 0.122, amphotericin B cut-off 0.104. MICs: fluconazole 32 mg/L, amphotericin B 1 mg/L. Ampho, amphotericin B; Fluco, fluconazole. Clinical Microbiology and Infection 2003 9, 441-444DOI: (10.1046/j.1469-0691.2003.00571.x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions